ES2627221T3 - Compuestos de heterocicloalquiloxibenzamida N-sustituidos y métodos de uso - Google Patents

Compuestos de heterocicloalquiloxibenzamida N-sustituidos y métodos de uso Download PDF

Info

Publication number
ES2627221T3
ES2627221T3 ES07855342.7T ES07855342T ES2627221T3 ES 2627221 T3 ES2627221 T3 ES 2627221T3 ES 07855342 T ES07855342 T ES 07855342T ES 2627221 T3 ES2627221 T3 ES 2627221T3
Authority
ES
Spain
Prior art keywords
piperidin
yloxy
benzamide
benzylpiperidin
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07855342.7T
Other languages
English (en)
Spanish (es)
Inventor
Rajinder Singh
Jiaxin Yu
Hui Hong
Sambaiah Thota
Xiang Xu
Ihab Darwish
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rigel Pharmaceuticals Inc
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2627221T3 publication Critical patent/ES2627221T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES07855342.7T 2006-12-28 2007-12-21 Compuestos de heterocicloalquiloxibenzamida N-sustituidos y métodos de uso Active ES2627221T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US88231206P 2006-12-28 2006-12-28
US882312P 2006-12-28
US98871907P 2007-11-16 2007-11-16
US988719P 2007-11-16
PCT/US2007/088742 WO2008083124A1 (en) 2006-12-28 2007-12-21 N-substituted-heterocycloalkyloxybenzamide compounds and methods of use

Publications (1)

Publication Number Publication Date
ES2627221T3 true ES2627221T3 (es) 2017-07-27

Family

ID=39204919

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07855342.7T Active ES2627221T3 (es) 2006-12-28 2007-12-21 Compuestos de heterocicloalquiloxibenzamida N-sustituidos y métodos de uso

Country Status (6)

Country Link
US (3) US8012955B2 (OSRAM)
EP (1) EP2079694B1 (OSRAM)
JP (1) JP5650404B2 (OSRAM)
CA (1) CA2674237C (OSRAM)
ES (1) ES2627221T3 (OSRAM)
WO (1) WO2008083124A1 (OSRAM)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010005298A (es) * 2007-11-16 2010-06-30 Rigel Pharmaceuticals Inc Compuestos de carboxamida, sulfonamida y amina para trastornos metabolicos.
EP2231666B1 (en) 2007-12-12 2015-07-29 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds for metabolic disorders
AU2009240643B2 (en) 2008-04-23 2014-03-06 Rigel Pharmaceuticals, Inc. Carboxamide compounds for the treatment of metabolic disorders
WO2010088392A1 (en) * 2009-01-28 2010-08-05 Rigel Pharmaceuticals, Inc. Carboxamide compounds and methods for using the same
GB0912975D0 (en) * 2009-07-24 2009-09-02 Syngenta Ltd Formulations
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011123681A1 (en) 2010-03-31 2011-10-06 Rigel Pharmaceuticals, Inc. Methods for using carboxamide, sulfonamide and amine compounds
WO2011142359A1 (ja) * 2010-05-10 2011-11-17 日産化学工業株式会社 スピロ化合物及びアディポネクチン受容体活性化薬
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
US8697911B2 (en) 2010-07-07 2014-04-15 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US9079880B2 (en) 2010-07-07 2015-07-14 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
PT2598483T (pt) * 2010-07-29 2020-10-12 Rigel Pharmaceuticals Inc Compostos heterocíclicos de ativação de ampk e métodos de utilização dos mesmos
WO2012054367A1 (en) 2010-10-19 2012-04-26 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US9005909B2 (en) 2011-01-06 2015-04-14 Rigel Pharmaceuticals, Inc. Whole blood assay for measuring AMPK activation
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013116491A1 (en) * 2012-02-01 2013-08-08 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds and methods for using them
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
CN105102448B (zh) 2013-02-28 2018-03-06 百时美施贵宝公司 作为rock1和rock2抑制剂的苯基吡唑衍生物
AR094929A1 (es) 2013-02-28 2015-09-09 Bristol Myers Squibb Co Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK
JP6664632B2 (ja) * 2013-09-30 2020-03-13 国立大学法人 東京大学 アディポネクチン受容体活性化化合物
US10059667B2 (en) 2014-02-06 2018-08-28 Merck Sharp & Dohme Corp. Antidiabetic compounds
US9832291B2 (en) 2015-01-12 2017-11-28 Cisco Technology, Inc. Auto-configurable transport stack
CN104803914B (zh) * 2015-03-05 2017-11-14 成都理工大学 作为Rho激酶抑制剂的六氢氮杂卓氧基苯甲酰胺类化合物
CN110372638B (zh) * 2018-04-13 2023-09-22 中国药科大学 哌嗪类ampk激动剂及其医药用途
CA3178994A1 (en) 2020-05-19 2021-11-25 Iyassu Sebhat Ampk activators
JP2023531726A (ja) 2020-06-26 2023-07-25 キャリーオペ，インク． Ａｍｐｋアクチベーター

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8406906D0 (en) 1984-03-16 1984-04-18 Akzo Nv Benzo-thiazole and benzothiophene derivatives
JPH0784462B2 (ja) 1986-07-25 1995-09-13 日清製粉株式会社 ベンゾイミダゾ−ル誘導体
GB9816837D0 (en) 1998-08-04 1998-09-30 Zeneca Ltd Amide derivatives
US7772432B2 (en) 1991-09-19 2010-08-10 Astrazeneca Ab Amidobenzamide derivatives which are useful as cytokine inhibitors
US5438064A (en) 1991-12-23 1995-08-01 American Home Products Corporation Derivatives of 4-anilinoquinoline-3-carboxamide as analgesic agents
US5332732A (en) 1992-09-11 1994-07-26 Mcneilab, Inc. Thiophene and pyridine antipsychotic agents
WO1995002405A1 (en) 1993-07-16 1995-01-26 Merck & Co., Inc. Benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin receptor antagonists
HU221138B1 (en) 1994-08-30 2002-08-28 Sankyo Co Condensed isoxazolyloxy- and -thioalkylamine derivatives, process for the preparation thereof and pharmaceutical compositions containing them
FR2738569B1 (fr) 1995-09-12 1997-11-28 Pf Medicament Nouveaux derives naphtamide de 3 beta-amino azabicyclo octane ou nonane, leur procede de preparation, leur utilisation a titre de medicament antipsychotique
PL195600B1 (pl) 1998-05-15 2007-10-31 Astrazeneca Ab Pochodne benzamidowe, sposób ich wytwarzania, zawierające je kompozycje farmaceutyczne oraz ich zastosowanie do wytwarzania leku do leczenia stanów medycznych powstających za pośrednictwem cytokin
BR9913654A (pt) 1998-08-28 2001-11-27 Scios Inc Inibidores de p-38alfa quinase
TR200102911T2 (tr) 1999-04-09 2002-01-21 Astrazeneca Ab Adamantan türevleri.
US6436965B1 (en) 2000-03-02 2002-08-20 Merck Frosst Canada & Co. PDE IV inhibiting amides, compositions and methods of treatment
US7273868B2 (en) 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
US7361678B2 (en) 2002-03-05 2008-04-22 Transtech Pharma, Inc. Azole derivatives and fused bicyclic azole derivatives as therapeutic agents
HU227197B1 (en) 2000-10-24 2010-10-28 Richter Gedeon Nyrt Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them
HK1054390B (en) 2000-12-22 2006-01-06 Schering Corporation Piperidine mch antagonists and their use in the treatment of obesity
US20030216582A1 (en) 2001-02-08 2003-11-20 Nicholas Nikolaides 2-carboxamide-benzimidazoles useful in the treatment and prevention of ischemic reperfusion injury
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
BR0212123A (pt) 2001-08-24 2004-07-20 Upjohn Co 7-aza[2.2.1]biciclo-heptanos substituìdos com arila para o tratamento de doenças
WO2003022856A1 (en) 2001-09-12 2003-03-20 Pharmacia & Upjohn Company Substituted 7-aza[2.2.1] bicycloheptanes for the treatment of diseases
WO2003028641A2 (en) 2001-10-01 2003-04-10 Taisho Pharmaceutical Co., Ltd. Mch receptor antagonists
JP2005523288A (ja) 2002-02-19 2005-08-04 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 疾病治療用の縮合した二環式−ｎ−架橋−複素環式芳香族カルボキサミド
WO2003072578A1 (en) 2002-02-20 2003-09-04 Pharmacia & Upjohn Company Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity
EP1500643A4 (en) 2002-04-03 2007-03-28 Dainippon Sumitomo Pharma Co BENZAMIDE DERIVATIVES
CA2484233A1 (en) 2002-05-13 2003-11-27 Eli Lilly And Company Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes
SE0202133D0 (sv) 2002-07-08 2002-07-08 Astrazeneca Ab Novel compounds
KR100962972B1 (ko) 2002-07-26 2010-06-09 주식회사유한양행 1-페닐피페리딘-3-온 유도체 및 그의 제조방법
WO2004022536A1 (en) * 2002-09-04 2004-03-18 Glenmark Pharmaceuticals Limited New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
UA79309C2 (en) 2002-09-06 2007-06-11 Janssen Pharmaceutica Nv Heterocyclic compounds
CN1744899A (zh) 2002-12-13 2006-03-08 史密丝克莱恩比彻姆公司 作为ccr5拮抗剂的哌啶衍生物
TW200503994A (en) 2003-01-24 2005-02-01 Novartis Ag Organic compounds
US7208491B2 (en) 2003-02-07 2007-04-24 Hoffmann-La Roche Inc. N-monoacylated o-phenylenediamines
MXPA05009059A (es) 2003-02-26 2005-10-19 Banyu Pharma Co Ltd Derivados de heteroarilcarbamoilbenceno.
PT1611088E (pt) 2003-04-07 2009-09-24 Pharmacyclics Inc Hidroxamatos como agentes terapêuticos
SE0301373D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
GB0314054D0 (en) 2003-06-17 2003-07-23 Pfizer Ltd Amide derivatives as selective serotonin re-uptake inhibitors
CN1832920A (zh) 2003-08-08 2006-09-13 特兰斯泰克制药公司 芳基和杂芳基化合物,组合物及其使用方法
NZ542711A (en) 2003-08-20 2008-03-28 Pharmacyclics Inc Acetylene derivatives as inhibitors of histone deacetylase
WO2005023761A2 (en) 2003-09-11 2005-03-17 Kemia, Inc. Cytokine inhibitors
BRPI0417156A (pt) * 2003-12-12 2007-03-06 Lilly Co Eli composto, composição farmacêutica, e, métodos para bloquear receptor mu, capa, delta ou combinação (heterodìmero) dos mesmos em mamìferos, para tratar e/ou prevenir doenças relacionadas com obesidade e obesidade, para suprimir apetite em um paciente, para efetuar perda de peso em um paciente obeso
PE20060315A1 (es) 2004-05-24 2006-05-15 Irm Llc Compuestos de tiazol como moduladores de ppar
JP4760139B2 (ja) * 2004-05-28 2011-08-31 田辺三菱製薬株式会社 ピロリジン誘導体およびその製法
JP4594386B2 (ja) 2004-06-02 2010-12-08 エフ．ホフマン−ラ ロシュ アーゲー ヒスタミン３受容体のリガンドとして有用なナフタレン誘導体
DK1761519T3 (da) 2004-06-21 2008-07-21 Hoffmann La Roche Indolderivater som histaminreceptorantagonister
JP2007277096A (ja) 2004-07-15 2007-10-25 Astellas Pharma Inc フェネチルニコチンアミド誘導体含有医薬
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
RU2391338C2 (ru) 2004-10-19 2010-06-10 Ф.Хоффманн-Ля Рош Аг Производные хинолина
EP1846409A1 (en) 2004-11-24 2007-10-24 Pfizer Limited Octahydropyrrolo[3,4-c]pyrrole derivatives
US7863449B2 (en) 2004-11-29 2011-01-04 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
AR052342A1 (es) 2004-12-21 2007-03-14 Janssen Pharmaceutica Nv Derivados sustituidos de triazolona,tetrazolona e imidazolona con actividad selectiva antagonista de alfa2c-adenoreceptores
AU2005318419A1 (en) 2004-12-23 2006-06-29 Chiesi Farmaceutici S.P.A. Azole derivatives with antimuscarinic activity
WO2006091862A2 (en) 2005-02-24 2006-08-31 Kemia, Inc. Cytokine inhibitors and their use in therapy
FR2884516B1 (fr) 2005-04-15 2007-06-22 Cerep Sa Antagonistes npy, preparation et utilisations
JP2008545009A (ja) 2005-06-30 2008-12-11 プロシディオン・リミテッド Ｇｐｃｒアゴニスト
EP1966199B1 (en) 2005-11-18 2010-10-20 F. Hoffmann-La Roche AG Azaindole-2-carboxamide derivatives
EP1960383B1 (en) 2005-11-30 2010-04-28 F. Hoffmann-la Roche AG 5-substituted indole-2-carboxamide derivatives
EP1968967B1 (en) 2005-11-30 2011-04-27 F. Hoffmann-La Roche AG 1,1-dioxo-thiomorpholinyl indolyl methanone derivatives for use as h3 modulators
BRPI0619268A2 (pt) 2005-11-30 2011-09-20 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3, uso dos compostos e método para o tratamento ou prevenção de obesidade e de diabetes do tipo ii em um ser humano ou animal
KR20080074217A (ko) 2005-12-09 2008-08-12 솔베이 파머슈티컬스 게엠베하 비만 및 이와 관련된 상태의 예방 또는 치료를 위한 신규의ｎ-설파모일-피페리딘아미드
KR20080080201A (ko) 2005-12-21 2008-09-02 쉐링 코포레이션 히스타민 ｈ3 길항제로서 유용한 치환된 아닐린 유도체
EP1981849A1 (en) 2005-12-29 2008-10-22 LEK Pharmaceuticals D.D. Heterocyclic compounds
US20090036429A1 (en) 2006-02-17 2009-02-05 Ohler Norman E Hydroxypiperidine Derivatives and Uses Thereof
CA2654792A1 (en) 2006-06-12 2007-12-21 Merck Frosst Canada Ltd. Azetidine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
JP2009539885A (ja) 2006-06-13 2009-11-19 メルク フロスト カナダ リミテツド ステアロイルコエンザイムａデルタ−９デサチュラーゼの阻害剤としてのアザシクロペンタン誘導体
US20080085915A1 (en) 2006-06-23 2008-04-10 Cyrus Becker Compounds and methods for the treatment of gastrointestinal and central nervous system disorders
TW200821303A (en) 2006-08-08 2008-05-16 Speedel Experimenta Ag Organic compounds
EP2141994A4 (en) 2007-04-26 2011-05-18 Avalon Pharmaceuticals POLYCYCLIC COMPOUNDS AND USES THEREOF
MX2010005298A (es) 2007-11-16 2010-06-30 Rigel Pharmaceuticals Inc Compuestos de carboxamida, sulfonamida y amina para trastornos metabolicos.
EP2231666B1 (en) 2007-12-12 2015-07-29 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds for metabolic disorders
AU2009240643B2 (en) 2008-04-23 2014-03-06 Rigel Pharmaceuticals, Inc. Carboxamide compounds for the treatment of metabolic disorders

Also Published As

Publication number Publication date
JP5650404B2 (ja) 2015-01-07
CA2674237A1 (en) 2008-07-10
US8697727B2 (en) 2014-04-15
CA2674237C (en) 2015-11-24
JP2010514788A (ja) 2010-05-06
US20140179738A1 (en) 2014-06-26
US8012955B2 (en) 2011-09-06
US20090186894A1 (en) 2009-07-23
US9181220B2 (en) 2015-11-10
US20110306767A1 (en) 2011-12-15
WO2008083124A1 (en) 2008-07-10
EP2079694B1 (en) 2017-03-01
EP2079694A1 (en) 2009-07-22

Similar Documents

Publication Publication Date Title
ES2627221T3 (es) Compuestos de heterocicloalquiloxibenzamida N-sustituidos y métodos de uso
TWI762544B (zh) 新穎cyp11a1抑制劑
ES2553340T3 (es) Compuestos de carboxamida, sulfonamida y amina para trastornos metabólicos
ES2244231T3 (es) Derivados de aminopirazol.
ES2581678T3 (es) Compuestos de carboxamida y métodos para usar los mismos
BRPI0820171B1 (pt) Compostos de carboxamida, sulfonamida e amina para distúrbiosmetabólicos, composição farmacêutica, e, uso dos mesmos
ES2237671T3 (es) Derivados de pirazol contra la sobreexpresion de tgf.
ES2423851T3 (es) Compuesto de aciltiourea o sal del mismo y uso del mismo
BR112013002112B1 (pt) Composto, composição farmacêutica, e, uso de um composto, ou de um respectivo sal farmaceuticamente aceitável, ou de uma composição
EA021119B1 (ru) Карбоксамидные соединения для лечения метаболических расстройств
TWI364420B (en) Novel piperazine amide derivatives
EP1680114A2 (en) Triazole compounds and uses related thereto
KR20140001904A (ko) Ｋｃｎｑ２／３ 조절제로서의 치환된 ６­아미노­니코틴아미드
KR20050074571A (ko) Ｉｐ 수용체 길항제로서의 페닐 또는 헤테로아릴 아미노알칸 유도체
WO2014000418A1 (en) Cyclopropanecarboxamido-substitute aromatic compounds as anti-tumor agents
KR20120131164A (ko) Ｐｇｄｓ 저해 작용을 갖는 피페라진 화합물
JP6434528B2 (ja) 置換ピリドン及びピラジノン、並びに好中球エラスターゼ活性の阻害剤としてのその使用
BRPI0715412A2 (pt) nitrato de Ésferes de piperidina
JPWO2018016458A1 (ja) ピペラジン誘導体
BRPI0609147A2 (pt) 1,3-tiazol-5-carboxamidas úteis como agentes quimioterapêuticos de cáncer
HK1164860B (en) Carboxamide compounds and methods for using the same
MXPA06004674A (en) Triazole compounds and uses related thereto